Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Sulindac (Aflodac; Algocetil; MK231; MK 231; MK-231), belonging to the arylalkanoic acid class of non-steroidal antiinflammatory drugs (NSAIDs), is a non-steroidal COX inhibitor, which potently inhibits prostaglandin synthesis. It has been used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in the body to the active NSAID, sulindac sulfide, a cyclooxgenase inhibitor that represses ras signaling, and sulindac sulfone, an antitumor agent, following oral administration in vivo.
ln Vitro |
TGF-β1-induced epithelial-mesenchymal transition (EMT) is efficiently inhibited by sulindac (MK-231) (500 μM, 48 hours), as evidenced by the overexpression of the epithelial marker E-cadherin and the downregulation of transcription factors and mesenchymal markers [1]. The TGF-β1-enhanced migration and invasion of A549 cells is inhibited by sulindac (500 μM, 48 h) [1]. TGF-β1-induced EMT is more effectively reversed by sulindac (500 μM, 48 h), and SIRT1 overexpression encourages TGF-β1-induced EMT[1].
|
---|---|
ln Vivo |
Sulindac (MK-231) (15 mg/kg po, bid; sulindac alone); 7.5 mg/kg po, bid; sulindac plus PD-L1)) demonstrated a marked decrease in tumor volume and an increase in CD8+ T cell infiltration. in tumor tissue following combination therapy treatment [2]. By inhibiting the NF-κB signaling pathway, sulindac (15 mg/kg orally twice daily; 7.5 mg/kg orally twice daily; sulindac with PD-L1) can downregulate PD-L1 and reduce exosome P[2]. By downregulating PD-L1 in combination treatment, sulindac (15 mg/kg po, bid; sulindac alone); 7.5 mg/kg po, bid; sulindac in conjunction with PD-L1)) increases the availability of PD-L1 Ab [2]. Prostaglandin E2 (PGE2) is not systemically inhibited by sulindac at low dosages (15 mg/kg po, bid; sulindac alone; 7.5 mg/kg po, bid; sulindac in conjunction with PD-L1)[2].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: A549 cells Tested Concentrations: 500 μM Incubation Duration: 48 h Experimental Results: Inhibit transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition in A549 cells. Immunofluorescence[1] Cell Types: A549 cells Tested Concentrations: 500 μM Incubation Duration: 48 h Experimental Results: Reversed SIRT-1 expression by TGF-β1 and inhibited the TGF-β1-induced cadherin switch. Cell Migration Assay [1] Cell Types: A549 cells Tested Concentrations: 500 μM Incubation Duration: 48 h Experimental Results: Inhibited migration, diminished resistance co-treatment with TGF-β1. Cell Invasion Assay[1] Cell Types: A549 cells Tested Concentrations: 500 μM Incubation Duration: 40 h; 48 h Experimental Results: Could effectively inhibit the TGF- β1-induced increase in invasion by lung cancer cells. |
Animal Protocol |
Animal/Disease Models: CT26 syngeneic mouse tumor model[2]
Doses: 15 mg/kg; 7.5 mg/kg Route of Administration: 15 mg/kg, po, bid (sulindac alone); 7.5 mg/kg po, bid (sulindac combination with PD- L1) Experimental Results: Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy. Cound effectively inhibit PD-L1 with no significant systematic toxicity. |
ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Approximately 90% absorbed in humans following oral administration. Sulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk. Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Hepatic metabolism is an important elimination pathway. Renal cl=68.12 +/- 27.56 mL/min [NORMAL (19-41 yrs)] Metabolism / Metabolites Undergoes two major biotransformations: reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Sulindac and its sulfide and sulfone metabolites undergo extensive enterohepatic circulation. Available evidence indicates that the biological activity resides with the sulfide metabolite. Side chain hydroxylation and hydration of the double bond also occur. Biological Half-Life The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours. |
Toxicity/Toxicokinetics |
Hepatotoxicity
Chronic therapy with sulindac is associated with a low rate of serum aminotransferase elevations, which are rarely severe and usually self-limited. Clinically apparent acute liver injury from sulindac is well known, but rare (~5 cases in 100,000 prescriptions and ~0.1% of users). Sulindac hepatotoxicity typically presents with fever, rash, nausea and vomiting and abdominal pain arising within a few days or weeks of starting the medication and followed shortly thereafter by jaundice. Occasionally, the onset may be delayed, particularly if therapy is intermittent. The clinical pattern suggests an allergic hepatitis and is somewhat similar to the hepatotoxicity of the sulfonamides. The pattern of serum enzyme elevations is usually hepatocellular or mixed at the onset, but may then become cholestatic. However, recovery is usually rapid once sulindac is stopped. Histology is consistent with an allergic hepatitis with spotty necrosis and marked inflammatory cell infiltration with prominence of eosinophils. In many instances, the features of hypersensitivity (such as facial swelling, desquamating rash, pharyngitis, stomatitis, lymphadenopathy, and hypotension) overshadow the liver injury and are more commonly the cause of death. Sulindac can also cause acute liver injury with a more delayed latency with few or no features of hypersensitivity. These cases are usually cholestatic and can be prolonged and lead to vanishing bile duct syndrome. Likelihood score: A (well established, although rare cause of clinically apparent liver injury). Effects During Pregnancy and Lactation ◉ Summary of Use during Lactation Because no information is available on the use of sulindac during breastfeeding, its relatively long half-life and glucuronide metabolite, other agents may be preferred, especially while nursing a newborn or preterm infant. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. Protein Binding At 1 mcg/ml concentrations, approximately 93% sulindac and 98% of its sulfide metabolite are bound to human serum albumin. |
References |
|
Additional Infomation |
Sulindac can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements.
Sulindac is a monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. It has a role as a non-steroidal anti-inflammatory drug, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an antineoplastic agent, a non-narcotic analgesic, an antipyretic, an analgesic, a prodrug, a tocolytic agent and an apoptosis inducer. It is a sulfoxide, a monocarboxylic acid and an organofluorine compound. It is functionally related to an acetic acid. Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2. Sulindac is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of sulindac is as a Cyclooxygenase Inhibitor. Sulindac is a commonly used nonsteroidal antiinflammatory drug (NSAID) that is available by prescription only and used predominantly to treat chronic arthritis. Sulindac is a rare, but well established cause of idiosyncratic, clinically apparent drug induced liver disease. Sulindac is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04) A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects. See also: Sulindac sodium (is active moiety of). Drug Indication For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis. FDA Label Mechanism of Action Sulindac's exact mechanism of action is unknown. Its antiinflammatory effects are believed to be due to inhibition of both COX-1 and COX-2 which leads to the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Pharmacodynamics Sulindac is a non-steroidal anti-inflammatory indene derivative, also possessing analgesic and antipyretic activities. |
Molecular Formula |
C20H17FO3S
|
|
---|---|---|
Molecular Weight |
356.41
|
|
Exact Mass |
356.088
|
|
CAS # |
38194-50-2
|
|
Related CAS # |
Sulindac sulfide;49627-27-2;Sulindac sodium;63804-15-9;Sulindac-d3;Sulindac sulfone;59973-80-7
|
|
PubChem CID |
1548887
|
|
Appearance |
White to yellow solid powder
|
|
Density |
1.4±0.1 g/cm3
|
|
Boiling Point |
581.6±50.0 °C at 760 mmHg
|
|
Melting Point |
182-185°C
|
|
Flash Point |
305.6±30.1 °C
|
|
Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
|
Index of Refraction |
1.673
|
|
LogP |
3.59
|
|
Hydrogen Bond Donor Count |
1
|
|
Hydrogen Bond Acceptor Count |
5
|
|
Rotatable Bond Count |
4
|
|
Heavy Atom Count |
25
|
|
Complexity |
616
|
|
Defined Atom Stereocenter Count |
0
|
|
SMILES |
CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
|
|
InChi Key |
MLKXDPUZXIRXEP-MFOYZWKCSA-N
|
|
InChi Code |
InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
|
|
Chemical Name |
(Z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8058 mL | 14.0288 mL | 28.0576 mL | |
5 mM | 0.5612 mL | 2.8058 mL | 5.6115 mL | |
10 mM | 0.2806 mL | 1.4029 mL | 2.8058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01843179 | Withdrawn | Drug: Cytarabine Drug: Sulindac |
Acute Myeloid Leukemia | Massachusetts General Hospital | January 2014 | Phase 2 |
NCT04542135 | Recruiting | Drug: Sulindac Pill Drug: Placebo |
Breast Cancer | Alison Stopeck | November 20, 2020 | Phase 2 |
NCT01636128 | Withdrawn | Drug: difluoromethylornithine Drug: Sulindac |
Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms |
Cancer Prevention Pharmaceuticals, Inc. | March 2014 | Phase 2 |
NCT01856322 | Terminated Has Results | Drug: Sulindac Drug: Placebo |
Colorectal Cancer Liver Metastasis |
National Cancer Institute (NCI) | April 2013 | Phase 2 |